Study of SPG601 in Adult Men With Fragile X Syndrome

Status Not yet recruiting

Clinical Trial Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.

Clinical Trial Description

This study is a Phase 2 randomized, double blind, placebo-controlled, cross over, single dose of SPG601 and matching Placebo in patients with Fragile X syndrome. This study will entail 2 in person clinic visits to administer oral doses of SPG601 or matching placebo. Participants will receive a dose of either SPG601 or placebo at first visit, and will cross over to receive the other product at the second visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06413537
Study type	Interventional
Source	Spinogenix
Contact	Sarah Richter
Phone	513-803-3324
Email	sarah.richter@cchmc.org
Status	Not yet recruiting
Phase	Phase 2
Start date	June 2024
Completion date	February 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05418049` - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge	Phase 2
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Completed	`NCT00965432` - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107	Phase 1
Completed	`NCT01120626` - Randomized Controlled Study of Donepezil in Fragile X Syndrome	Phase 2
Completed	`NCT01204151` - Teaching Math Skills to Individuals With Fragile X Syndrome	N/A
Active, not recruiting	`NCT00334971` - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women	N/A
Enrolling by invitation	`NCT06139172` - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities	N/A
Recruiting	`NCT04977986` - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome	Phase 3
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Completed	`NCT03722290` - Metformin in Children and Adults With Fragile X Syndrome	Phase 2
Completed	`NCT05030129` - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome	Phase 2
Recruiting	`NCT05957549` - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG	N/A
Recruiting	`NCT04141163` - Metformin in Patients With Fragile X	Phase 1/Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT00858689` - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Enrolling by invitation	`NCT03802799` - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS	Phase 2/Phase 3
Recruiting	`NCT05295277` - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation	`NCT03836300` - Parent and Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT01725152` - Ganaxolone Treatment in Children With Fragile X Syndrome	Phase 2